Recce Pharmaceuticals Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infections
August 23, 2023 08:00 ET
|
Recce Pharmaceuticals
Patients with bacterial infections successfully treated with RECCE® 327 (R327)Deadly bacterial pathogens treated with R327 include those identified by the World Health Organization as major threats to...
Recce Pharmaceuticals Provides Positive Update on Patients Treated with RECCE® 327 Under “Special Access Scheme”
August 10, 2023 08:00 ET
|
Recce Pharmaceuticals
RECCE® 327 as a gel formulation (R327G) demonstrated a positive clinical response in the treatment of multiple antibiotic-resistant infections under Therapeutic Goods Administration (TGA) Special...
Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives
August 04, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...
Recce Pharmaceuticals Receives Second Canadian Scientific Research and Experimental Development Rebate
August 02, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to...
Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research
August 01, 2023 08:00 ET
|
Recce Pharmaceuticals
Cohort dosing at Scientia Clinical Research has been completed ahead of scheduleDemonstrated RECCE® 327 (R327) to be safe and well-tolerated in male and female subjects at two faster infusion rates of...
Recce Pharmaceuticals to Present at the 2023 Military Health System Research Symposium (MHSRS)
July 31, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, July 31, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced a...
Recce Pharmaceuticals Doses Subjects in Rapid Infusion Phase I/II UTI Clinical Trial of RECCE® 327 at Scientia Clinical Research
July 26, 2023 08:00 ET
|
Recce Pharmaceuticals
Dosing at Scientia Clinical Research has commenced with first male and female subjects dosed ahead of scheduleSubjects who received RECCE® 327 (R327) were dosed at faster infusion rates than subjects...
Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE® 327 as an Intravenous Infusion Formulation
July 20, 2023 08:25 ET
|
Recce Pharmaceuticals
Highlights: Independent examiners confirm Phase I study of RECCE® 327 (R327) in 80 human subjects across eight cohorts achieved all primary study endpoints, met international regulatory standards,...
Recce Pharmaceuticals Receives A$801,604 Research and Development (R&D) Rebate Advance
July 13, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, July 13, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to...
Recce Pharmaceuticals Announces First Cohort Dosed in RECCE® 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial
July 11, 2023 08:00 ET
|
Recce Pharmaceuticals
Highlights: First cohort in Phase I/II urinary tract infection (UTI) rapid infusion intravenous (IV) study successfully dosed 2,500mg of RECCE® 327 (R327), resulting in high peak urine...